ArticleFrontiers in immunology2026

Immune recovery following switch from EFV-based regimens to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed immunological non-responders: a 144-week real-world cohort study in China.

Honghong Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.